Velsera's Global Data Network Revolutionizes Real-World Data Access for Pharma and Biotech

Velsera's Global Data Network: Transforming Pharmaceutical and Biotech Access to Data



In the world of healthcare technology, few innovations are as impactful as Velsera's Global Data Network (GDN). This revolutionary data ecosystem is reshaping how pharmaceutical and biotech companies can access and utilize real-world, longitudinal clinicogenomic data on a massive scale. As Velsera continues to broaden its capabilities, the influence of the GDN is becoming increasingly evident in accelerating drug development processes that span over 175 million patient records worldwide.

A New Era of Data Accessibility



Historically, accessing clinical and genomic data has been a cumbersome and time-consuming endeavor for life sciences organizations. According to Jamie Littlejohns, the CEO of Velsera, the traditional process of data acquisition often takes years to complete—years that the fast-paced biotech and pharma industries cannot afford to waste. With an astonishing 97% of healthcare data remaining unutilized, there exists an urgent need for a more efficient way to link researchers with the critical data they require.

Velsera’s GDN addresses these challenges by providing a federated network that allows for secure and compliant access to diverse datasets while ensuring data remains under the control of its originating institutions. This innovative technology facilitates seamless integration of previously siloed data, including electronic medical records (EMR), genomics, proteomics, and more.

Global Reach and Diverse Data Sources



The Global Data Network spans over 50 data providers beyond U.S. borders, with growing representation from Europe, Asia, and Latin America. This global data footprint ensures that the GDN serves various therapeutic areas, with particular attention to oncology, immunology, cardiometabolic diseases, and neurology. By making use of local data sources, Velsera not only enhances the relevance of its offerings but also champions patient privacy and regulatory compliance—two critical aspects in healthcare data handling.

Purpose-Built for Pharma's Challenges



Pharmaceutical companies face a myriad of challenges in research and development (R&D), from target discovery to clinical trial optimization and biomarker development. The GDN is specifically designed to provide tailored solutions to these R&D pain points, targeting critical applications such as:
  • - Patient Stratification: Helping teams identify the right patient cohorts for clinical trials.
  • - Biomarker Discovery: Assisting in the identification of biomarkers to inform drug development.
  • - Label Expansion: Supporting drugs in gaining broader indications.
  • - AI/ML Applications: Facilitating predictive model development and machine learning training.
  • - Diagnostic Development: Enabling the creation of companion diagnostics and assays.

The GDN is powerfully equipped to support a wide range of applications, with approximately 60% of client engagements tapping into clinical and omics data. This versatility allows it to accommodate numerous high-impact use cases across various research and development efforts.

Accelerating Insights While Upholding Compliance



One of Velsera’s strengths lies in its customer-centric approach. Their team of data scientists and domain experts collaborate directly with clients to specify, source, and harmonize the necessary datasets. This partnership model has proven effective, with 80% of data requests fulfilled within weeks. This drastic enhancement in speed allows biopharma partners to achieve actionable insights much sooner, compressing timelines previously measured in years.

In its efforts to reduce barriers to adoption, Velsera provides various engagement options—ranging from multi-year collaborative agreements to short-term access—empowering teams of all sizes to explore innovative use cases with agility.

As Jamie Littlejohns puts it, "We're not just offering data; we're offering the infrastructure and expertise to transform that data into actionable outputs. This is what R&D teams need to thrive in today's fast-moving landscape."

About Velsera



Velsera emerged from the recent merger of esteemed entities including Seven Bridges and PierianDx, officially establishing itself in 2023. The company’s mission is to serve as a comprehensive platform that bridges clinical care and discovery within the realm of precision medicine. Velsera operates on a global scale, making substantial contributions to the fields of clinical diagnostics and life sciences.

As we continue to observe the advancements made possible by Velsera’s innovative GDN, one thing becomes clear: the future of healthcare data accessibility is here, and its impact will resonate across all facets of medical research and patient care.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.